Современное лечение ВИЧ : лечение возрастных пациентов.2017/Contemporary Management of HIV. Management of Aging Patients.2017
In this downloadable slideset, Edgar Turner Overton, MD, and Program Director Joseph J. Eron, Jr., MD, review key data on managing aging patients with HIV.
Source: Contemporary Management of HIV
Date Posted: 4/24/2017
Современное лечение ВИЧ : АРТ как профилактика.Contemporary Management of HIV...hivlifeinfo
Contemporary Management of HIV. Antiretroviral Therapy As Prevention.2016
In this downloadable slideset, Kenneth Mayer, MD, and Program Director Eric S. Daar, MD, review key data and optimal approaches for pre- and post-exposure prophylaxis in patients at risk for HIV infection.
Format: Microsoft PowerPoint (.ppt)
File size: 2.13 MB
Современное лечение ВИЧ: лечение ВИЧ у пациентов с вирусными гепатитами.Conte...hivlifeinfo
Современное лечение ВИЧ: лечение ВИЧ у пациентов с вирусными гепатитами.Contemporary Management of HIV. Managing HIV in Viral Hepatitis Coinfection.2016
In this downloadable slideset, David L. Wyles, MD, and Program Director Eric S. Daar, MD, review key data and optimal approaches for ART management in patients with HIV and viral hepatitis coinfection.
Format: Microsoft PowerPoint (.ppt)
File size: 1.85 MB
Топ достижений лечения ВИЧ в 2017 г / Top Advances in ART for 2017hivlifeinfo
Top Advances in ART for 2017
In this downloadable slideset, Joel E. Gallant, MD, MPH, provides a comprehensive update on ART management.
Format: Microsoft PowerPoint (.ppt)
File size: 579 KB
Date posted: 3/29/2017
Современное лечение ВИЧ: АРТ у пациентов с сопутствующими заболеваниями.Conte...hivlifeinfo
Современное лечение ВИЧ:АРТ у пациентов с сопутствующими заболеваниями.//Contemporary Management of HIV. Managing ART in HIV-Infected Patients With Common Comorbidities. 2016
In this downloadable slideset, David A. Wohl, MD, and Program Director Eric S. Daar, MD, review key data and optimal approaches for managing ART in the context of common comorbidities.
Format: Microsoft PowerPoint (.ppt)
File size: 3.51 MB
Contemporary Management of HIV.How Common Comorbidities Affect ART Management...hivlifeinfo
In this downloadable slideset, expert faculty review key data and offer important guidance on managing HIV treatment in patients with frequently encountered comorbidities, including cardiovascular disease, osteopenia, and HCV coinfection.
Format: Microsoft PowerPoint (.ppt)
File size: 2.27 MB
Date posted: 2/12/2018
Современное лечение ВИЧ: лечение ВИЧ у женщин.2017/Contemporary Management of...hivlifeinfo
In this downloadable slideset, Kathleen E. Squires, MD, and Program Director Joseph J. Eron, Jr., MD, review key data and optimal strategies in caring for HIV-infected women, including ART safety and efficacy in women, reproductive health management, ART and pregnancy, and preventing HIV infection in women.
Format: Microsoft PowerPoint (.ppt)
File size: 1.59 MB
Date posted: 4/25/2017
Современное лечение ВИЧ: модификация АРТ у пациентов с вирусной супрессией и ...hivlifeinfo
Современное лечение ВИЧ: модификация АРТ у пациентов с вирусной супрессией и у пациентов с вирусологической неудачей. /Contemporary Management of HIV. Modifying Antiretroviral Therapy in Virologically Suppressed Patients and Those With Treatment Failure.2016
In this downloadable slideset, W. David Hardy, MD, and Program Director Eric S. Daar, MD review key data and optimal approaches for modifying ART in patients who are virologically suppressed or have experienced treatment failure.
Format: Microsoft PowerPoint (.ppt)
File size: 2.07 MB
Современное лечение ВИЧ : АРТ как профилактика.Contemporary Management of HIV...hivlifeinfo
Contemporary Management of HIV. Antiretroviral Therapy As Prevention.2016
In this downloadable slideset, Kenneth Mayer, MD, and Program Director Eric S. Daar, MD, review key data and optimal approaches for pre- and post-exposure prophylaxis in patients at risk for HIV infection.
Format: Microsoft PowerPoint (.ppt)
File size: 2.13 MB
Современное лечение ВИЧ: лечение ВИЧ у пациентов с вирусными гепатитами.Conte...hivlifeinfo
Современное лечение ВИЧ: лечение ВИЧ у пациентов с вирусными гепатитами.Contemporary Management of HIV. Managing HIV in Viral Hepatitis Coinfection.2016
In this downloadable slideset, David L. Wyles, MD, and Program Director Eric S. Daar, MD, review key data and optimal approaches for ART management in patients with HIV and viral hepatitis coinfection.
Format: Microsoft PowerPoint (.ppt)
File size: 1.85 MB
Топ достижений лечения ВИЧ в 2017 г / Top Advances in ART for 2017hivlifeinfo
Top Advances in ART for 2017
In this downloadable slideset, Joel E. Gallant, MD, MPH, provides a comprehensive update on ART management.
Format: Microsoft PowerPoint (.ppt)
File size: 579 KB
Date posted: 3/29/2017
Современное лечение ВИЧ: АРТ у пациентов с сопутствующими заболеваниями.Conte...hivlifeinfo
Современное лечение ВИЧ:АРТ у пациентов с сопутствующими заболеваниями.//Contemporary Management of HIV. Managing ART in HIV-Infected Patients With Common Comorbidities. 2016
In this downloadable slideset, David A. Wohl, MD, and Program Director Eric S. Daar, MD, review key data and optimal approaches for managing ART in the context of common comorbidities.
Format: Microsoft PowerPoint (.ppt)
File size: 3.51 MB
Contemporary Management of HIV.How Common Comorbidities Affect ART Management...hivlifeinfo
In this downloadable slideset, expert faculty review key data and offer important guidance on managing HIV treatment in patients with frequently encountered comorbidities, including cardiovascular disease, osteopenia, and HCV coinfection.
Format: Microsoft PowerPoint (.ppt)
File size: 2.27 MB
Date posted: 2/12/2018
Современное лечение ВИЧ: лечение ВИЧ у женщин.2017/Contemporary Management of...hivlifeinfo
In this downloadable slideset, Kathleen E. Squires, MD, and Program Director Joseph J. Eron, Jr., MD, review key data and optimal strategies in caring for HIV-infected women, including ART safety and efficacy in women, reproductive health management, ART and pregnancy, and preventing HIV infection in women.
Format: Microsoft PowerPoint (.ppt)
File size: 1.59 MB
Date posted: 4/25/2017
Современное лечение ВИЧ: модификация АРТ у пациентов с вирусной супрессией и ...hivlifeinfo
Современное лечение ВИЧ: модификация АРТ у пациентов с вирусной супрессией и у пациентов с вирусологической неудачей. /Contemporary Management of HIV. Modifying Antiretroviral Therapy in Virologically Suppressed Patients and Those With Treatment Failure.2016
In this downloadable slideset, W. David Hardy, MD, and Program Director Eric S. Daar, MD review key data and optimal approaches for modifying ART in patients who are virologically suppressed or have experienced treatment failure.
Format: Microsoft PowerPoint (.ppt)
File size: 2.07 MB
Why, when, and how to use pre exposure prophylaxis for hiv acquisition. 2014Hivlife Info
In this downloadable slide set, Marcy S. Gelman, RN, MSN, MPH, and Kevin M. O’Hara, PA, review essential considerations for midlevel providers administering PrEP
Format: Microsoft PowerPoint (.ppt)
File size: 825 KB
Date posted: 9/29/2014
Новые данные с конференции по ВИЧ-инфекции CROI 2017/Clinical Impact of New D...hivlifeinfo
Clinical Impact of New Data From CROI 2017
Expert faculty members Joel E. Gallant, MD, MPH, and Charles B. Hicks, MD, summarize key studies from this important annual conference.
Format: Microsoft PowerPoint (.ppt)
File size: 1.25 MB
Date posted: 3/3/2017
Contemporary Management of HIV.How Aging Affects ART Management.2018hivlifeinfo
In this downloadable slideset, Expert Faculty review key data on managing aging patients with HIV.
Format: Microsoft PowerPoint (.ppt)
File size: 720 KB
Date posted: 3/7/2018
Современное лечение ВИЧ: новые подходы к оптимизации АРТ/Contemporary Managem...hivlifeinfo
Вопросы, связанные с АРТ первого ряда, смена арв-стратегии для пациентов с вирусной супрессией, акцентом на возрастающую роль новыхантиретровирусных стратегий.
Integrating Recent Data When Selecting First-line Antiretroviral Therapy.2015...Hivlife Info
Joseph J. Eron Jr., MD
W. David Hardy, MD
Paul E. Sax, MD
How do leading experts select first-line antiretroviral therapy for their HIV-infected patients?
Review these downloadable slides for key clinical trial data and the latest DHHS recommendations for first-line antiretroviral therapy.
Начало АРТ впервые.Наилучшая практика.Best Practices in Antiretroviral Therap...hivlifeinfo
Best Practices in Antiretroviral Therapy: Initiating First-line Therapy
In this downloadable slideset, Charles B. Hicks, MD, discusses data on initiating antiretroviral therapy in HIV-infected patients.
Format: Microsoft PowerPoint (.ppt)
File size: 2.16 MB
HIV Alert:ART Considerations for Aging Patients.2018hivlifeinfo
In this downloadable slideset, Eric S. Daar, MD, and David A. Wohl, MD, provide expert recommendations for older patients with HIV, both in terms of ART selection and general management.
Format: Microsoft PowerPoint (.ppt)
File size: 545 KB
Date posted: 2/12/2018
АРТ в 2016-2017 гг: неизменная потребность в индивидуализации лечения для улу...hivlifeinfo
In this downloadable slideset, Danielle Ciuffetelli, PharmD, and Elly Fatehi, PharmD, BCPS, review important considerations when selecting initial ART and explore how formularies can be better managed to ensure delivery of optimal care for diverse populations of HIV-infected patients. Illustrative cases provide useful examples of key factors involved in treatment selection, including comorbidities, patient preferences and disposition, concomitant medications, and childbearing potential.
Format: Microsoft PowerPoint (.ppt)
File size: 2.46 MB
Date posted: 1/10/2017
Сравнение режимов лечения ВИЧ в разрезе различных клинических сценариев.ART...hivlifeinfo
This downloadable slideset summarizes optimal evidence-based antiretroviral therapy management strategies for a series of challenging clinical cases and is based on a satellite symposium presented at HIV Glasgow 2016.
Format: Microsoft PowerPoint (.ppt)
File size: 1.32 MB
Date posted: 11/11/2016
In this downloadable slideset, Joel E. Gallant, MD, MPH, reviews the evidence behind the latest antiretroviral guidelines and offers a glimpse at upcoming agents currently under investigation.
Format: Microsoft PowerPoint (.ppt)
File size: 3.00 MB
Date posted: 6/15/2015
Современное лечение ВИЧ.Усилить или не усилить : преимущества и недостатки бу...hivlifeinfo
Современное лечение ВИЧ.Усилить или не усилить : преимущества и недостатки бустированных режимов АРТ / Contemporary Management of HIV.To Boost or Not to Boost-Advantages and Disadvantages of Boosted ART.2017
In this downloadable slideset, Eric S. Daar, MD, and Program Director Joseph J. Eron, Jr., MD, review advantages and disadvantages of boosted ART regimens for managing patients with HIV.
Format: Microsoft PowerPoint (.ppt)
File size: 514 KB
Date posted: 6/16/2017
Современное лечение ВИЧ: новые парадигмы в АРТ / Contemporary Management of H...hivlifeinfo
Набор слайдов c рассмотрением важных вопросов об АРТ первого ряда, арв-препаратами пролонгированного действия и схемами АРТ с двумя препаратами, акцент в публикации на роль новых стратегий.
Модификация схем АРТ у пациентов с вирусной супрессией и после вирусологичес...hivlifeinfo
Best Practices in Antiretroviral Therapy: Switching ART in Virologically Suppressed Patients and After Virologic Failure
In this downloadable slideset, Joseph J. Eron, Jr., MD, discusses data on changing antiretroviral therapy in HIV-infected patients.
Format: Microsoft PowerPoint (.ppt)
File size: 2.06 MB
Современное лечение ВИЧ: когда начинать, чем начинать. Contemporary Managemen...hivlifeinfo
.Contemporary Management of HIV. When to Start, What to Start.2016/Современное лечение ВИЧ: когда начинать, чем начинать.
In this downloadable slideset, Daniel R. Kuritzkes, MD, and Program Director Eric S. Daar, MD review key data and optimal approaches for first-line ART with contemporary HIV regimens.
Format: Microsoft PowerPoint (.ppt)
File size: 2.53 MB
Date posted: 2/9/2016
In this downloadable slideset, Joseph J. Eron, Jr., MD, reviews the evidence behind the latest antiretroviral guidelines and offers a glimpse at potential future agents and strategies currently under investigation.
Format: Microsoft PowerPoint (.ppt)
File size: 2.06 MB
Date posted: 6/1/2016
Should Integrase Inhibitors Be Your First Choice When Starting HIV Therapy- E...Hivlife Info
In this downloadable slideset, Joseph J. Eron, Jr., MD, and Daniel Kuritzkes, MD, review key data on the evolving use of INSTIs in patients beginning HIV therapy.
Format: Microsoft PowerPoint (.ppt)
File size: 2.29 MB
Choosing Among Current Antiretroviral Regimens.The Relevance of Drug–Drug Int...hivlifeinfo
In this downloadable slideset, Jürgen K. Rockstroh, MD, reviews how selection of antiretroviral therapy is influenced by drug–drug interactions and differing antiretroviral genetic barriers to resistance.
Format: Microsoft PowerPoint (.ppt)
File size: 1.17 MB
Date posted: 11/4/2016
Why, when, and how to use pre exposure prophylaxis for hiv acquisition. 2014Hivlife Info
In this downloadable slide set, Marcy S. Gelman, RN, MSN, MPH, and Kevin M. O’Hara, PA, review essential considerations for midlevel providers administering PrEP
Format: Microsoft PowerPoint (.ppt)
File size: 825 KB
Date posted: 9/29/2014
Новые данные с конференции по ВИЧ-инфекции CROI 2017/Clinical Impact of New D...hivlifeinfo
Clinical Impact of New Data From CROI 2017
Expert faculty members Joel E. Gallant, MD, MPH, and Charles B. Hicks, MD, summarize key studies from this important annual conference.
Format: Microsoft PowerPoint (.ppt)
File size: 1.25 MB
Date posted: 3/3/2017
Contemporary Management of HIV.How Aging Affects ART Management.2018hivlifeinfo
In this downloadable slideset, Expert Faculty review key data on managing aging patients with HIV.
Format: Microsoft PowerPoint (.ppt)
File size: 720 KB
Date posted: 3/7/2018
Современное лечение ВИЧ: новые подходы к оптимизации АРТ/Contemporary Managem...hivlifeinfo
Вопросы, связанные с АРТ первого ряда, смена арв-стратегии для пациентов с вирусной супрессией, акцентом на возрастающую роль новыхантиретровирусных стратегий.
Integrating Recent Data When Selecting First-line Antiretroviral Therapy.2015...Hivlife Info
Joseph J. Eron Jr., MD
W. David Hardy, MD
Paul E. Sax, MD
How do leading experts select first-line antiretroviral therapy for their HIV-infected patients?
Review these downloadable slides for key clinical trial data and the latest DHHS recommendations for first-line antiretroviral therapy.
Начало АРТ впервые.Наилучшая практика.Best Practices in Antiretroviral Therap...hivlifeinfo
Best Practices in Antiretroviral Therapy: Initiating First-line Therapy
In this downloadable slideset, Charles B. Hicks, MD, discusses data on initiating antiretroviral therapy in HIV-infected patients.
Format: Microsoft PowerPoint (.ppt)
File size: 2.16 MB
HIV Alert:ART Considerations for Aging Patients.2018hivlifeinfo
In this downloadable slideset, Eric S. Daar, MD, and David A. Wohl, MD, provide expert recommendations for older patients with HIV, both in terms of ART selection and general management.
Format: Microsoft PowerPoint (.ppt)
File size: 545 KB
Date posted: 2/12/2018
АРТ в 2016-2017 гг: неизменная потребность в индивидуализации лечения для улу...hivlifeinfo
In this downloadable slideset, Danielle Ciuffetelli, PharmD, and Elly Fatehi, PharmD, BCPS, review important considerations when selecting initial ART and explore how formularies can be better managed to ensure delivery of optimal care for diverse populations of HIV-infected patients. Illustrative cases provide useful examples of key factors involved in treatment selection, including comorbidities, patient preferences and disposition, concomitant medications, and childbearing potential.
Format: Microsoft PowerPoint (.ppt)
File size: 2.46 MB
Date posted: 1/10/2017
Сравнение режимов лечения ВИЧ в разрезе различных клинических сценариев.ART...hivlifeinfo
This downloadable slideset summarizes optimal evidence-based antiretroviral therapy management strategies for a series of challenging clinical cases and is based on a satellite symposium presented at HIV Glasgow 2016.
Format: Microsoft PowerPoint (.ppt)
File size: 1.32 MB
Date posted: 11/11/2016
In this downloadable slideset, Joel E. Gallant, MD, MPH, reviews the evidence behind the latest antiretroviral guidelines and offers a glimpse at upcoming agents currently under investigation.
Format: Microsoft PowerPoint (.ppt)
File size: 3.00 MB
Date posted: 6/15/2015
Современное лечение ВИЧ.Усилить или не усилить : преимущества и недостатки бу...hivlifeinfo
Современное лечение ВИЧ.Усилить или не усилить : преимущества и недостатки бустированных режимов АРТ / Contemporary Management of HIV.To Boost or Not to Boost-Advantages and Disadvantages of Boosted ART.2017
In this downloadable slideset, Eric S. Daar, MD, and Program Director Joseph J. Eron, Jr., MD, review advantages and disadvantages of boosted ART regimens for managing patients with HIV.
Format: Microsoft PowerPoint (.ppt)
File size: 514 KB
Date posted: 6/16/2017
Современное лечение ВИЧ: новые парадигмы в АРТ / Contemporary Management of H...hivlifeinfo
Набор слайдов c рассмотрением важных вопросов об АРТ первого ряда, арв-препаратами пролонгированного действия и схемами АРТ с двумя препаратами, акцент в публикации на роль новых стратегий.
Модификация схем АРТ у пациентов с вирусной супрессией и после вирусологичес...hivlifeinfo
Best Practices in Antiretroviral Therapy: Switching ART in Virologically Suppressed Patients and After Virologic Failure
In this downloadable slideset, Joseph J. Eron, Jr., MD, discusses data on changing antiretroviral therapy in HIV-infected patients.
Format: Microsoft PowerPoint (.ppt)
File size: 2.06 MB
Современное лечение ВИЧ: когда начинать, чем начинать. Contemporary Managemen...hivlifeinfo
.Contemporary Management of HIV. When to Start, What to Start.2016/Современное лечение ВИЧ: когда начинать, чем начинать.
In this downloadable slideset, Daniel R. Kuritzkes, MD, and Program Director Eric S. Daar, MD review key data and optimal approaches for first-line ART with contemporary HIV regimens.
Format: Microsoft PowerPoint (.ppt)
File size: 2.53 MB
Date posted: 2/9/2016
In this downloadable slideset, Joseph J. Eron, Jr., MD, reviews the evidence behind the latest antiretroviral guidelines and offers a glimpse at potential future agents and strategies currently under investigation.
Format: Microsoft PowerPoint (.ppt)
File size: 2.06 MB
Date posted: 6/1/2016
Should Integrase Inhibitors Be Your First Choice When Starting HIV Therapy- E...Hivlife Info
In this downloadable slideset, Joseph J. Eron, Jr., MD, and Daniel Kuritzkes, MD, review key data on the evolving use of INSTIs in patients beginning HIV therapy.
Format: Microsoft PowerPoint (.ppt)
File size: 2.29 MB
Choosing Among Current Antiretroviral Regimens.The Relevance of Drug–Drug Int...hivlifeinfo
In this downloadable slideset, Jürgen K. Rockstroh, MD, reviews how selection of antiretroviral therapy is influenced by drug–drug interactions and differing antiretroviral genetic barriers to resistance.
Format: Microsoft PowerPoint (.ppt)
File size: 1.17 MB
Date posted: 11/4/2016
Cardiovascular Disease in HIV-Infected Patients.Predict It and Prevent It.2015Hivlife Info
In this downloadable slideset, Priscilla Y. Hsue, MD, and David A. Wohl, MD, discuss data on using traditional and newer markers and modalities to predict and prevent cardiovascular disease in HIV-infected patients.
Format: Microsoft PowerPoint (.ppt)
File size: 3.21 MB
Date posted: 7/16/2015
Сердечно-сосудистые заболевания у ВИЧ-инфицированных пациентов : предсказать ...hivlifeinfo
Cardiovascular Disease in HIV-Infected Patients.Predict It and Prevent It. 2015
In this downloadable slideset, Priscilla Y. Hsue, MD, and David A. Wohl, MD, discuss data on using traditional and newer markers and modalities to predict and prevent cardiovascular disease in HIV-infected patients.
Format: Microsoft PowerPoint (.ppt)
File size: 3.21 MB
Date posted: 7/16/2015
Joseph Eron, M.D., of University of North Carolina at Chapel Hill, presents "The State of the Art in HIV Cure Research – Hope or Hype: What Does It Mean for Patients" at AIDS Clinical Rounds
Risk factors of chronic liver disease amongst patients receiving care in a Ga...iosrjce
IOSR Journal of Dental and Medical Sciences is one of the speciality Journal in Dental Science and Medical Science published by International Organization of Scientific Research (IOSR). The Journal publishes papers of the highest scientific merit and widest possible scope work in all areas related to medical and dental science. The Journal welcome review articles, leading medical and clinical research articles, technical notes, case reports and others.
Wesley Campbell, M.D., of U.S. Navy Medicine, presents "Neurocognitive Changes in Newly Diagnosed Patient with Low CD4: Implications for Prognosis and Employment"
Cathy Logan, MD, of the UC San Diego AntiViral Research Center, presents "Solid Organ Transplantation and HIV" at AIDS Clinical Rounds on August 29, 2014
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Jens Lundgren, CHIP
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Christian B. Ramers, M.D., M.P.H., of Family Health Centers of San Diego, presents "The HCV Treatment Revolution: A View from the Community Health Center" for AIDS Clinical Rounds at UC San Diego
Clinical Impact of New HIV Data From CROI 2019hivlifeinfo
March 4-7, 2019; Seattle, Washington
In this downloadable slideset, expert faculty members summarize key studies from this important annual conference.
Format: Microsoft PowerPoint (.ppt)
File Size: 576 KB
Released: March 22, 2019
Best Practices in the Management of HCV/HIV Coinfection: Optimizing Treatment...Hivlife Info
Jürgen K. Rockstroh, MD, provides an update on the importance of HCV screening and the latest emerging treatment options for patients with HCV/HIV coinfection.
Дискуссии о здоровом старении с ВИЧ /Key Slides on Healthy Aging With HIV.2022hivlifeinfo
Дискуссии о здоровом старении с ВИЧ
Узнайте о медицинских и немедицинских проблемах, с которыми сталкиваются стареющие пациенты с ВИЧ, включая дополнительные проблемы, с которыми сталкиваются пожилые женщины и пожилые люди, живущие в условиях ограниченных ресурсов.
Основы ведения АРТ у многократно леченных пациентов 2022 / Foundations of ART...hivlifeinfo
Основы ведения АРТ у многократно леченных пациентов (2022)
Тактики ведения пациентов с большим опытом лечения, включая анализ резистентности, последние рекомендации и данные по новым схемам АРТ
Современное лечение и профилактика ВИЧ : передовые стратегии лечения у пациен...hivlifeinfo
Стратегии смены АРТ у пациентов с вирусной супрессией, включая смену АРТ при резистентности, рекомендации по инъекционным препаратам длительного действия , смена АРТ до или во время беременности
Ключевые слайды по индивидуальному выбору АРТ / Key Slides on Individualized ...hivlifeinfo
Слайды с последними данные и рекомендациями по выбору АРТ, как для пациентов, ранее не получавших лечения, так и пациентов с вирусологической супрессией. Оценки разных вариантов лечения, индивидуализация АРТ для женщин детородного возраста и во время беременности, пациентов с опортунистическими инфекциями и новые данные об исследовательских стратегиях АРТ.
Современное лечение ВИЧ: модификация АРТ у пациентов с вирусологической супре...hivlifeinfo
Современное лечение ВИЧ: модификация АРТ у пациентов с вирусологической супрессией (2021) / Contemporary Management of HIV: Modifying ART in Virologically Suppressed Patients 2021
Key Slides on ART for HIV : Evolving Concepts and Innovative Strategies.2020hivlifeinfo
Expert-authored slides on evolving ART concepts, including simplification to 2-drug therapy, ART safety during pregnancy, weight gain, and long-acting injectable ART.
File Size: 580 KB
Released: October 20, 2020
Clinical Impact of New Data From AIDS 2020hivlifeinfo
current ART in principal populations, including older patients and women who become pregnant; metabolic outcomes during ART; HIV and COVID-19; investigational ART strategies; and HIV prevention.
Слайдсет о новом в лечении ВИЧ.Key Slides on What’s Hot in HIV Treatment.2020 hivlifeinfo
Expert-authored slides on the latest issues relating to HIV care, featuring patient cases and considerations for optimal treatment approaches. Topics include integrating newer ARVs, individualizing ART for women of childbearing potential and during pregnancy, adverse events during ART, and anticipated roles of emerging ART strategies.
Гиперлипопротеидемия(а) как опасное генетически обусловленное нарушение липид...hivlifeinfo
Гиперлипопротеидемия(а) как опасное генетически обусловленное нарушение липидного обмена и фактор риска атеротромбоза и сердечно-сосудистых заболеваний
Липопротеид(а) [Лп(а)] представляет собой сложный надмолекулярный комплекс, принадлежащий к апоВ100 содержащим липопротеидам. Лп(а) состоит из ЛНП-подобной частицы, в которой молекула апобелка В100 ковалентно связана дисульфидной связью с уникальной полиморфной молекулой апобелка(а). Концентрация Лп(а) генетически контролируется, при этом варьирует в очень широком диапазоне. Повышенный уровень Лп(а) является независимым фактором риска атеросклероза коронарных, сонных и периферических артерий, ИБС и стеноза аортального клапана, сопутствующих сердечно-сосудистых осложнений, а также осложнений после операций реваскуляризации миокарда. Несмотря на это, уровень Лп(а) по-прежнему не учитывается в стратификации риска сердечно-сосудистых заболеваний. Отчасти, это может быть связано с тем, что ни современная лекарственная терапия, ни новые поколения биологических гиполипидемических препаратовтерапия практически не влияют на концентрацию Лп(а), за исключением 20-30% снижения Лп(а) никотиновой кислотой и ингибиторами пропротеиновой конвертазы субтилизин-кексин 9 типа (PCSK9).
Лекция освящает современные представления о Лп(а), как факторе риска сердечно-сосудистых заболеваний, возможности и целесообразности его определения, а также посвящена современным возможностям коррекции гиперлипопротеидемии(а).
Физическая активность и физические тренировки как метод профилактики сердечно...hivlifeinfo
Чушкин М.И., Мандрыкин С.Ю., Карпина Н.Л., Попова Л.А. Физическая активность и физические тренировки как метод профилактики сердечно-сосудистых заболеваний. Кардиология. 2018;58(9S):10-18
Большое число данных свидетельствует, что функциональные возможности кардиореспираторной системы являются не менее важным фактором прогноза летальности, чем курение, артериальная гипертензия, ожирение, гиперхолестеринемия, СД. Пациенты с большей физической активностью имеют значительно меньший риск ССЗ, чем пациенты, ведущие неактивный образ жизни. В данном обзоре авторы показали возможности оценки физической активности и основные положения назначения физических тренировок для сохранения и повышения функциональных возможностей кардиореспираторной системы.
Key Slides on Individualizing ART Management Based on Treatment Safety and To...hivlifeinfo
Обзор последних рекомендаций DHHS , индивидуализация лечения в отдельных группах пациентов, минимизация побочных эффектов и межлекарственных взаимодействий
Современное лечение ВИЧ.Обобщённые данные с конференции CROI 2020 / Contempor...hivlifeinfo
Современное лечение ВИЧ.Обобощенные данные с конференции CROI 2020 / Contemporary Management of HIV.Integrating New Data From CROI 2020
Широкий спектр вопросов, включая стратегии АРТ на поздних стадихя заболевания, менеджмент ожирения, метаболические исходы АРТ, данные по АРТ во время беременности и пр
Format: Microsoft PowerPoint (.ppt)
File Size: 554 KB
Released: April 14, 2020
Свобода интернета 2018: делегирование репрессий.Доклад Международной Агорыhivlifeinfo
«Настоящий доклад посвящен обзору вмешательства в свободу интернета в России в 2018 году и основан на данных постоянного мониторинга ситуации, который мы ведем более 10 лет.
Как обычно, доклад состоит из двух основных разделов, первый из которых посвящен описанию результатов мониторинга с приведением наиболее показательных примеров, а второй – авторской оценке состояния свободы интернета. В приложении даны сводные результаты мониторинга в виде таблицы со ссылкой на дату, источник, регион и вид ограничения по каждому известному эпизоду, а также карта нарушений, на которой цветом обозначен уровень относительной свободы интернета в отдельных субъектах Федерации.»
https://guides.files.bbci.co.uk/bbc-russian/AGORA_Freedom-of-the-Internet-2018.pdf
Confronting the Challenges of HIV Care in an Aging Population.2019hivlifeinfo
Еxpert faculty use case-based examples to examine considerations for aging patients with HIV. Topics include ART modification, bone loss, renal impairment, cardiovascular risk, and cognitive decline.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Современное лечение ВИЧ : лечение возрастных пациентов.2017/Contemporary Management of HIV. Management of Aging Patients.2017
1. Contemporary Management of HIV:
Management of Aging Patients
This program is supported by an independent educational grant
from ViiV Healthcare.
2. Please feel free to use, update, and share some or all of these
slides in your noncommercial presentations to colleagues or
patients
When using our slides, please retain the source attribution:
These slides may not be published, posted online, or used in
commercial presentations without permission. Please contact
permissions@clinicaloptions.com for details
Slide credit: clinicaloptions.com
About These Slides
3. Program Director and Core Faculty
Program Chair
Joseph J. Eron, Jr., MD
Professor of Medicine and
Epidemiology
University of North Carolina
School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina
Core Faculty
Edgar Turner Overton, MD
Associate Professor
Department of Medicine
Division of Infections Diseases
University of Alabama at
Birmingham
Birmingham, Alabama
5. Decreased Life Expectancy in Older HIV-Positive
Adults in Modern ART Era
Population-based cohort study of survival in HIV-infected pts (n = 2440) and
uninfected controls matched by age and sex (n = 14,588) in Denmark
HIV-Negative
Controls
1996-2014
2006-2014
2000-2005
1996-1999
HIV-Positive Pts
1.00
0.75
0.50
0.25
0
ProbabilityofSurvival
50 60 70 80
Age (Yrs)
Legarth RA, et al. J Acquir Immune Defic Syndr. 2016;71:213-218. Slide credit: clinicaloptions.com
6. ATHENA: Older Pts Becoming More Prevalent in
the HIV-Infected Population
Observational cohort of
10,278 HIV-infected pts in the
Netherlands
Modeling study projections:
– Proportion of HIV-positive pts
≥ 50 yrs of age to increase
from 28% in 2010 to 73% in
2030
– Median age of HIV-positive
pts on combination ART to
increase from 43.9 yrs in
2010 to 56.6 yrs in 2030
Smit M, et al. Lancet Infect Dis. 2015;15:810-818.
ProportionofHIV-PositivePts
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
2010 2015 2020 20302025
> 70 yrs of age
60-70 yrs of age
50-60 yrs of age
40-50 yrs of age
30-40 yrs of age
< 30 yrs of age
Slide credit: clinicaloptions.com
7. AGEhIV: Older HIV-Infected Pts at Increased
Risk for Multiple Comorbidities
Cross-sectional analysis of comorbidity prevalence in prospective cohort study of HIV-infected
pts (n = 540) vs controls (n = 524) 45 yrs of age or older
Schouten J, et al. Clin Infect Dis. 2014;59:1787-1797. Slide credit: clinicaloptions.com
0
20
40
60
80
100
45-49 50-54 55-59 60-64 ≥ 65
Pts(%)
HIV Infected
45-49 50-54 55-59 60-64 ≥ 65
HIV Uninfected
3+
2
1
0
Mean number of comorbidities
Number of participants
0.83
184
1.18
126
1.34
97
1.52
58
1.96
55
0.79
193
0.75
130
1.11
84
1.08
66
1.51
41
Age (Yrs)
Comorbidities, n
8. AGEhIV: Older HIV-Infected Pts at Increased
Risk for Multiple Comorbidities
Cross-sectional analysis of comorbidity prevalence in prospective cohort study of HIV-
infected pts (n = 540) vs controls (n = 524) ≥ 45 yrs of age
Schouten J. Clin Infect Dis. 2014;59:1787-1797.
Slide credit: clinicaloptions.com
Pts(%)
50
30
20
10
0
40
P < .001
P = .018 P = .008 P = .044
HIV-uninfected pts
HIV-infected pts
9. Factors Related to Non-AIDS Comorbidities in
HIV-Infected Pts
Warriner AH, et al. Infect Dis Clin North Am. 2014;28:457-476. Slide credit: clinicaloptions.com
AGING
Chronic HIV infection
ART toxicity
HCV and other coinfections
Genetics
Obesity, exercise, diet,
smoking
Inflammation and fibrosis
Dyslipidemia
Insulin resistance
Decreased physical functioning
Cardiovascular
Renal
Metabolic
Functional
Neuropsychiatric
Factors Conditions End Organ Disease
10. HIV and Inflammation
Hypothesis: HIV infection induces a persistent inflammatory
response, resulting in pathogenic responses and end-organ
disease
Elevated levels of inflammatory markers, including IL-6,
associated with increased risk of non-AIDS comorbidities and
mortality in HIV-infected pts[1-4]
ART partially reduces some inflammatory biomarker levels;
however, they may still remain elevated vs healthy HIV-
uninfected individuals[3,4]
Slide credit: clinicaloptions.com
1. Tenorio AR, et al. J Infect Dis. 2014;210:1248-1259. 2. So-Armah KA, et al. J Acquir Immune Defic
Syndr. 2016;72:206-213. 3. Nixon DE, et al. Curr Opin HIV AIDS. 2010;5:498-503. 4. Neuhaus J, et al.
J Infect Dis. 2010;201:1788-1795.
11. Inflammation Associated With Disease in
Treated HIV Infection
Mortality[1-4]
Cardiovascular disease[5]
Cancer[6]
Venous thromboembolism[7]
Type 2 diabetes[8]
Radiographic emphysema[9]
Renal disease[10]
Bacterial pneumonia[11]
Cognitive dysfunction[11]
Depression[13]
Functional impairment/frailty[14]
References in slidenotes. Slide credit: clinicaloptions.com
13. Case 1: Presentation
60-yr-old white man presents for care after HIV diagnosis
Slide credit: clinicaloptions.com
Characteristic Finding
HIV-1 RNA 42,000 copies/mL
CD4+ cell count 225 cells/mm3
HLA-B*5701 status Negative
Resistance/GT No mutations
Blood pressure 145/86 mm Hg
BMI 27.5
Lipid profile TC 196 mg/dL, LDL 125 mg/dL, HDL 25 mg/dL, TG 175 mg/dL
Renal markers Serum Cr 1.5 mg/dL eGFR 54 mL/min/1.73m2
Medications Hydrochlorothiazide 25 mg QD Simvastatin 10 mg QD
Other Does not exercise Smoker
14. 60-yr-old, ART-naive, HIV-infected man
Hypertension, hyperlipidemia, CKD, elevated CVD risk
Overweight, smoker
Comedications: hydrochlorothiazide, simvastatin
What is the most important intervention to
reduce cardiovascular disease risk for this pt?
A. Smoking cessation
B. Mediterranean diet initiation
C. Statin change
D. Daily aspirin initiation
E. ART initiation
Please respond using your mobile device 12345678910
15. CVD Mortality Higher in HIV-Infected Pts, Even
With Virologic Suppression
Analysis of CVD-related mortality in HIV-infected pts in New York City HIV
Surveillance Registry 2001-2012 (N = 145,845)
– 71% male; median age: 49 yrs
From 2001-2012, CVD mortality increased in HIV-infected pts (from 6% to 15%)
while decreasing in the general population
Age-adjusted rate of CVD mortality markedly decreased for HIV-infected pts
with virologic suppression
– HIV-1 RNA ≥ 400 copies/mL, 8.02/1000 PY
– HIV-1 RNA < 400 copies/mL, 3.99/1000 PY
– General population, 3.22/1000 PY
Slide credit: clinicaloptions.comHanna DB, et al. Clin Infect Dis. 2016;63:1122-1129.
16. Hypertension Is Increasing and More Prevalent
Among HIV-Infected Pts
Analysis of HTN in HIV-infected pts in
UNC CFAR HIV Clinical Cohort, 1996-
2013 (N = 3141)[1]
Hypertension incidence
– 1996: 1.68 cases/100 PY
– 2013: 5.35 cases/100 PY
Key risk factors
– Age – Obesity
– Diabetes – Renal insufficiency
– Nadir CD4+ cell count < 500 cells/mm3
Analysis of HTN in HIV-infected (n =
527) and HIV-uninfected (n = 517)
persons in AGEhIV cohort[2]
HTN rate higher among HIV-infected
vs HIV-uninfected persons
– 48% vs 36%; aOR: 1.65; 95% CI:
1.25-2.19
Slide credit: clinicaloptions.com
1. Okeke NL, et al. Clin Infect Dis. 2016;63:242-248.
2. van Zoest RA, et al. Clin Infect Dis. 2016;63:205-213.
17. 60-yr-old, ART-naive, HIV-infected man
HIV-1 RNA 42,000 copies/mL, CD4+ cell count 225 cells/mm3, HLA-B*5701 negative, WT virus
BP 145/86, BMI 27.5, TC 196 mg/dL, LDL 125 mg/dL, HDL 25 mg/dL, TG 175 mg/dL
Serum Cr 1.5 mg/dL, eGFR 54 mL/min/1.73m2
Comedications: hydrochlorothiazide, simvastatin
Which of the following ART regimens would you
recommend for the case pt?
A. DRV/RTV + FTC/TAF
B. DTG/ABC/3TC
C. DTG + FTC/TAF
D. EVG/COBI/FTC/TAF
E. RAL + FTC/TAF
F. Something else
Please respond using your mobile device 12345678910
18. START: Immediate vs Deferred ART by Age
Subgroup analysis of START, in which HIV-infected, ART-naive adults with CD4+ cell count
> 500 cells/mm3 randomized to immediate or deferred* ART (N = 4685)
Molina JM, et al. IAC 2016. Abstract THAB0201. Slide credit: clinicaloptions.com
*Until CD4+ cell count ≤ 350 cells/mm3, AIDS-related event, or event requiring ART.
Mos
Aged < 30 Yrs
PtsWithSeriousAIDSor
Non-AIDS–RelatedEvent(%)
16
14
12
10
8
6
4
2
0
600 12 24 36 48
2.6
1.3
Immediate ART
Deferred ART
Aged 30-49 Yrs
16
14
12
10
8
6
4
2
0
600 12 24 36 48
3.3
1.3
Aged ≥ 50 Yrs
16
14
12
10
8
6
4
2
0
600 12 24 36 48
11.7
2.9
19. DHHS HIV Guidelines: ART Considerations for
Older Pts
ART is recommended for all pts regardless of CD4+ cell count; especially important
for older pts due to
– Greater risk of serious non-AIDS complications
– Potentially a blunted immunologic response to ART
Adverse drug events from ART and concomitant drugs may occur more frequently
in older HIV-infected pts
– Bone, kidney, metabolic, cardiovascular, and liver health should be monitored closely
Polypharmacy is common in older HIV-infected pts
– Greater risk of drug–drug interactions
HIV experts should collaborate with primary care providers and other specialists to
optimize the medical care of older HIV-infected pts with complex comorbidities
Slide credit: clinicaloptions.comDHHS Guidelines. July 2016.
20. DHHS: First-line Therapy Recommendations
Slide credit: clinicaloptions.com
Third Agent NRTI Backbone Daily Tablets
INSTI-Based Regimens
DTG ABC/3TC 1
DTG FTC/TAF or FTC/TDF 2
EVG/COBI FTC/TAF or FTC/TDF 1
RAL FTC/TAF or FTC/TDF 3
PI-Based Regimen
DRV/RTV FTC/TAF or FTC/TDF 3
DHHS Guidelines. July 2016.
21. DHHS: Considerations for Initial ART Based on
Age-Related Comorbidity
Scenario Consider Avoiding
Options for Consideration
Agent Caveat
CKD (eGFR
< 60 mL/min)
TDF, especially in
RTV-containing
regimens
TAF
ABC/3TC
DRV/RTV + RAL
LPV/RTV + 3TC
If eGFR > 30 mL/min
If HLA-B*5701 negative; 3TC requires dose
adjustment if CrCl < 50 mL/min
If TAF or ABC cannot be used; if HIV-1 RNA
< 100,000 copies/mL and CD4+ cell count
> 200 cells/mm3
If TAF or ABC cannot be used; 3TC dose
adjustment if CrCl < 50 mL/min
Osteoporosis TDF TAF
ABC/3TC If HLA-B*5701 negative
CVD risk ABC
Hyperlipidemia PI/RTV or PI/COBI
EVG/COBI
DTG
RAL
TDF more favorable lipid
effects vs ABC or TAF
Slide credit: clinicaloptions.comDHHS Guidelines. July 2016.
22. What comedications most often require adjustment or
precipitate a change in ART for your older HIV-infected pts?
A. Antacids
B. Cardiac medications
C. Corticosteroids (inhaled or injection)
D. Diabetes medications
E. Lipid-lowering medications
F. Something else
Please respond using your mobile device 12345678910
23. ATHENA and Swiss HIV Cohort Studies:
Polypharmacy Among HIV-Infected Pts on ART
5.2% of pts 50-64 yrs of age and 14.2% of pts
≥ 65 yrs of age received ≥ 4 meds other than ART
Predicts that 20% of pts will be receiving
≥ 3 meds other than ART in 2030
Slide credit: clinicaloptions.com1. Smit M, et al. Lancet Infect Dis. 2015;15:810-818. 2. Hasse B, et al. Clin Infect Dis. 2011:53;1130-1139.
ATHENA Modeling Study[1]
16,000
14,000
12,000
10,000
8000
6000
4000
2000
0
People(n)
3+ comedications
2 comedications
1 comedication
No comedication
2010 2015 2020 2025 2030
Swiss HIV Cohort Study (N = 8444)[2]
Prospective Observational Study
< 50 Yrs 50-64 Yrs ≥ 65 Yrs
100
80
60
40
20
0
Participants(%)
n = 5761 n = 2233 n = 450
No comedication
1 comedication
2 comedication
3 comedications
4+ comedications
24. Key Interactions: INSTI-Containing ART
Regimens
Consider www.hiv-druginteractions.org to assist with identifying
potential interactions for all regimens
Regimen Key Drug–Drug Interaction Considerations
All INSTIs[1-5] Use caution with/avoid simultaneous polyvalent cation-containing
antacids
DTG/3TC/ABC[1]
DTG + FTC/TDF or FTC/TAF[2,6,7]
Dose adjust metformin (diabetes medication)
EVG/COBI/FTC/TDF[3,4]
EVG/COBI/FTC/TAF[4,5]
Avoid lovastatin, simvastatin (lipid-lowering agents), salmeterol
(asthma/COPD medication)
Avoid/use caution with inhaled, injected, or systemic steroids
RAL + FTC/TDF or FTC/TAF[6-8] No notable comedications to avoid for RAL aside from
aluminum/magnesium antacids
Slide credit: clinicaloptions.comReferences in slidenotes.
25. Key Interactions: Boosted PI- or NNRTI-
Containing ART Regimens
Regimen Key Drug–Drug Interactions
ATV/RTV + FTC/TDF or
FTC/TAF[1-5]
DRV/RTV + FTC/TDF or
FTC/TAF[1,3-6]
Avoid lovastatin, simvastatin (lipid-lowering agents), salmeterol
(asthma/COPD medication)
Use caution with other lipid-lowering agents (eg, atorvastatin,
rosuvastatin, pravastatin)
Use caution with/avoid specific antiarrhythmics (eg, amiodarone)
Avoid PPIs (eg, omeprazole) with ATV
Use caution with/avoid inhaled, injected, or systemic steroids
RPV/FTC/TDF[7]
RPV/FTC/TAF[8]
Avoid PPIs (eg, omeprazole, pantoprazole), dexamethasone
EFV/FTC/TDF[1,9] No notable comedications to avoid for EFV; consider alternative
corticosteroid to dexamethasone
Slide credit: clinicaloptions.comReferences in slidenotes.
26. Approach to Lipid-Lowering (Statin) Therapy
HIV-infected patients are at increased risk for ASCVD[1,2]
– ART can cause increases in triglycerides and total, VLDL, LDL, and HDL cholesterol
Prescribing statins can be challenging due to DDIs, insulin resistance, adverse events, and
increased pill burden[1]
Slide credit: clinicaloptions.com
Aspect of Statin Therapy Recommendation
Goal of therapy CVD risk reduction[1]
Screening
A fasting lipid panel should be obtained in all newly diagnosed HIV-infected pts[1,3]
Lipid screening annually[3]
Treatment
Statin therapy is first-line therapy for elevated LDL and non-HDL cholesterol[1]
Moderate- or high-intensity statin therapy should be considered[1]
Lifestyle therapy is the recommended first step[4]
Other Patient-provider discussion is central to decisions on drug treatment[1]
References in slidenotes.
27. Slide credit: clinicaloptions.comDubé MP. Lipid management. 2015. p. 241-255.
PI- or COBI-Containing Regimens
High-Intensity Statin Moderate-Intensity Statin Low-Intensity Statin
Atorvastatin 20 mg Atorvastatin 10 mg Pravastatin 10-20 mg
Rosuvastatin 10-20 mg Rosuvastatin 5 mg Fluvastatin 20-40 mg
Pravastatin 40-80 mg* Pitavastatin 1 mg
Pitavastatin 2-4 mg
Simvastatin and lovastatin are contraindicated for pts receiving a PI or COBI
*With darunavir, reduce pravastatin to 20-40 mg
NNRTI-, RAL-, or DTG-Containing Regimens
High-Intensity Statin Moderate-Intensity Statin Low-Intensity Statin
Atorvastatin 40-80 mg Atorvastatin 10-20 mg Pravastatin 10-20 mg
Rosuvastatin 20 mg Rosuvastatin 10 mg Fluvastatin 20-40 mg
Pravastatin 40-80 mg Pitavastatin 1 mg
Pitavastatin 2-4 mg Lovastatin 20 mg
Lovastatin 40 mg Simvastatin 10 mg
Simvastatin 20-40 mg
Suggested Statins in the Setting of ART
All doses daily.
28. Case 1: Take-Home Points
Slide credit: clinicaloptions.com
Observation Recommendations
HIV-infected pts have
increased CVD risk
Virologic suppression can reduce CVD risk
Controlling other metabolic comorbidities (many of which occur more
frequently in HIV-infected pts) can also reduce the risk of CVD
• HTN, T2DM, CKD, lipid abnormalities
Lifestyle modification (exercise, diet, smoking cessation) may also
reduce risk
ART can increase dyslipidemia
Manage lipids with statin therapy; consider potential DDIs with PI- or
COBI-containing regimens
Numerous challenges exist in
treating HIV infection in aging
pts
Assess comorbidities and potential interplay with ART regimens
• Bone, lipid, or cardiovascular abnormalities can be exacerbated by
specific therapeutics
Consider polypharmacy and potential DDIs
29. Case 2: Aging Patient Developing
Comorbidities on ART
30. Case 2: Presentation
62-yr-old, HIV-infected white man returns for routine visit
Characteristic Finding
Current ART regimen/HIV status Stable suppression on EFV/FTC/TDF for 12 yrs; current HIV-1 RNA undetectable
CD4+ cell count 425 cells/mm3; nadir count 50 cells/mm3
Comorbidities Hypertension and hyperlipidemia, both controlled
Medications Hydrochlorothiazide 25 mg QD Simvastatin 10 mg QD
Vital signs Temp 98.6ºF; pulse 80 and regular, BP 130/76 mm Hg, RR 12
Weight 160 lbs (lost 10 lbs in last yr)
Other
Reports low energy and fatigue;
wants to sleep all the time
Denies depressed mood, easy
bruisability, hair loss
No fevers/chills/night sweats
No lymphadenopathy or edema
Normal urine function
Normal lab values: CBC, CMP, thyroid
studies, B12 level
Colonoscopy 2 yrs ago: normal
No STIs; HAV and HBV immune; HCV
Ab negative
Slide credit: clinicaloptions.com
31. 62-yr-old man with stable virologic suppression on EFV/FTC/TDF
Controlled hypertension, hyperlipidemia; comedications: hydrochlorothiazide, simvastatin
Recent weight loss; reports low energy and fatigue; wants to sleep all the time
Denies depression; lab values and other tests negative/normal
Which of the following is the most likely
explanation for his presentation?
A. Occult malignancy
B. Severe depression
C. Medicine toxicity
D. Atrial fibrillation
E. Frailty
F. Something else
Please respond using your mobile device 12345678910
32. The Concept of Frailty
Multisystem clinical syndrome that reflects biological rather than chronological age; regarded as
an end-stage state[1]
Associated with loss of functional homeostasis, inability to recover fully after stressors, and
morbidity and excess mortality[1]
Other tools: FRAIL Scale, Study of Osteoporotic Fractures (SOF) index, Clinical Frailty Scale[3-5]
Slide credit: clinicaloptions.comReferences in slidenotes.
Fried Frailty Phenotype[2]
Frailty Characteristic Clinical Criteria*
Shrinking Unintentional weight loss (> 10 lbs) in prior year, sarcopenia
Muscle weakness Poor grip strength (lowest quintile by sex, BMI)
Poor endurance/exhaustion Self-reported exhaustion
Slowness Walking time per 15 ft (slowest quintile by sex, height)
Low activity Low kcal/week expenditure (lowest quintile by sex)
*Frailty defined as presence of ≥ 3 criteria; prefrailty as presence of 1-2 criteria.
33. Frailty More Prevalent in HIV-Infected vs
HIV-Uninfected Persons
Assessment of frailty* in HIV-infected (n = 521) and -uninfected (n = 513) pts in AGEhIV cohort
Frailty/prefrailty associated with HIV infection, advanced age, smoking, chronic HCV infection, depression,
low BMI,† and waist-to-hip ratio
Slide credit: clinicaloptions.comKooij KW, et al. AIDS. 2016;30:241-250.
Frailty Prevalence by Age/HIV Status Individual Frailty Criteria
*Using Fried frailty phenotype. †In HIV-infected patients only.
Nonfrail
Prefrail
Frail
0
20
40
60
80
100
Pts(%)
HIV Status
Age (Yrs)
0
5
10
15
20
HIV infected
HIV uninfected
Pts(%)
25
30
P < .001
P < .001P < .001
P < .001
P = .04
+ -
45-50
+ -
50-55
+ -
55-60
+ -
60-65
+ -
> 65
34. Frailty Associated With Increased Risk of
Hospitalization
Prospective evaluation of frailty in HIV-infected pts (N = 445)[1]
– Frailty prevalence: 9%
– Predictors of frailty: higher number of comorbidities and past OIs, increased
depressive symptoms, antidepressant use, lower serum albumin, unemployment
– Frailty associated with excess hospitalizations and longer inpatient hospital stays
ALIVE: evaluation of frailty in HIV-infected (n = 417) and HIV-uninfected
individuals (n = 886)[2]
– Frailty prevalence: 12.1% overall; 13.4% among HIV-infected pts
– Frailty significantly associated with all-cause hospitalization rates (HR: 1.41; 95%
CI: 1.06-1.87; P < .05)
Slide credit: clinicaloptions.com
1. Önen NF, et al. J Infect. 2009;59:346-352.
2. Piggott DA, et al. J Gerontol A Biol Sci Med Sci. 2017;72:389-394.
35. Frailty Risk Factors in Aging HIV-Positive Pts
Slide credit: clinicaloptions.comErlandson KM, et al. IAS 2011. Abstract TUPE124.
Incidence(%)
Diabetes
Frail (n = 33)
Prefrail (n = 185)
Nonfrail (n = 141)
Risk Factors (OR: Frail vs Nonfrail)
Neurologic
Disease
Psychiatric
Disease
CVD Unhealthy
Weight
Arthritis Osteoporosis Viral
Hepatitis
HR: 5.1
P = .007
HR: 3.9
P < .001
HR: 3.9
P = .002
HR: 3.8
P = .067
HR: 3.7
P = .004
HR: 3.6
P = .001
HR: 3.5
P = .022
HR: 3.3
P = .004
0
20
40
60
80
36. In your practice, which of the following is the most
common reason for modifying ART in your older pts?
A. Bone disease (osteopenia/osteoporosis)
B. Renal disease (decrease in glomerular filtration rate)
C. Neurocognitive impairment
D. Polypharmacy and pharmacologic interactions
E. Metabolic complications (diabetes or lipid concerns)
F. Something else
Please respond using your mobile device 12345678910
37. Case 2: Recent Fracture and Diminished Bone
Health
62-yr-old pt returns for a visit; has suffered a wrist fracture in a fall
Characteristic Finding
Current ART regimen/HIV status Stable suppression on X + FTC/TDF for 12 yrs; current HIV-1 RNA undetectable
CD4+ cell count 425 cells/mm3
Comorbidities Hypertension and hyperlipidemia, both controlled
Medications Hydrochlorothiazide 25 mg QD Simvastatin 10 mg QD
Vital signs Temp 98.6ºF; pulse 80 and regular, BP 130/76 mm Hg, RR 12
Weight 160 lbs (lost 10 lbs in last yr)
Other
Reports low energy and fatigue;
wants to sleep all the time
Denies depressed mood, easy
bruisability, hair loss
No fevers/chills/night sweats; no
lymphadenopathy or edema
Normal urine function and lab values
No STIs; HAV and HBV immune; HCV
Ab negative
Bone health
Recently suffered a wrist fracture in a fall
DXA T-scores: L-spine: -2.6; femoral neck: -2.7; hip: -2.6
38. 62-yr-old man with stable virologic suppression on EFV/FTC/TDF
Controlled hypertension, hyperlipidemia; comedications: hydrochlorothiazide, simvastatin
Recent weight loss; reports low energy and fatigue; wants to sleep all the time
Recent wrist fracture; DXA T-scores: L-spine: -2.6; femoral neck: -2.7; hip: -2.6
Discussion: How would you adjust the pt’s ART
regimen?
NRTI Backbone
A. ABC/3TC
B. FTC/TAF
C. FTC/TDF
D. Something else
E. I would not adjust this pt’s
backbone
Third Agent
A. DTG
B. EVG/COBI
C. DRV/RTV
D. Something else
E. I would not adjust this pt’s third
agent
39. Fracture Prevalence Is Increased in Older HIV-
Infected Pts
Meta-analysis: HIV-positive pts had 6.4-fold increased risk of low BMD and 3.7-fold
increased risk of osteoporosis[1]
8525 HIV-infected pts compared with 2,208,792 uninfected pts in Partners HealthCare
System, 1996-2008[2]
Slide credit: clinicaloptions.com
Women Men
Age (Yrs)
7.0
6.0
5.0
4.0
3.0
2.0
1.0
0
FracturePrevalence/
100Persons
30-39 40-49 50-59 60-69 70-79
P = .002
(overall comparison)
HIV
Non-HIV
HIV
Non-HIV
Age (Yrs)
7.0
6.0
5.0
4.0
3.0
2.0
1.0
0
FracturePrevalence/
100Persons
20-29 30-39 40-49 50-59 60-69
P < .0001
(overall comparison)
1. Brown TT, et al. AIDS. 2006;20:2165-2174. 2. Triant V, et al. J Clin Endocrinol Metab. 2008;93:3499-3504.
40. Recommendations for Evaluation of Bone
Disease in HIV
Brown TT, et al. Clin Infect Dis. 2015;60:1242-1251. Slide credit: clinicaloptions.com
HIV-Infected Population Assessment Monitoring
Men 40-49 yrs of age
Premenopausal women
≥ 40 yrs of age
Assess risk of fragility
fracture using FRAX
For pts with FRAX score ≤ 10%,
monitor FRAX in 2-3 yrs
For pts with FRAX score > 10%,
perform DXA
Men ≥ 50 yrs of age
Postmenopausal women
Pts with fragility fracture
history, receiving chronic
glucocorticoids, or at high
risk of falls
Assess BMD using DXA
For pts with advanced osteopenia,
monitor DXA in 1-2 yrs
For pts with mild or moderate
osteopenia, monitor DXA in 5 yrs
For pts started on bisphosphonates
(significantly reduced BMD or fracture
history), repeat DXA in 2 yrs
41. ART Considerations for Pts With Bone
Complications
DHHS considerations[1]
– Consider avoiding TDF: associated with greater decrease in BMD
along with renal tubulopathy, urine phosphate wasting, and
osteomalacia
– Consider ABC/3TC or FTC/TAF
Significantly greater BMD loss with PI-based regimens vs RAL-
based regimens (when used with FTC/TDF)[2]
DTG/ABC/3TC associated with less bone turnover than
EFV/TDF/FTC[3]
1. DHHS Guidelines. July 2016. 2. Brown TT, et al. J Infect Dis. 2015;212:1241-1249.
3. Tebas P, et al. AIDS. 2015;29:2459-2464. Slide credit: clinicaloptions.com
42. Case 2: Take-Home Points
Observation Recommendations
Frailty is more prevalent among
HIV-infected vs HIV-uninfected
individuals
Assess pts for frailty; consider Fried Frailty Phenotype or
other available tests
Fracture prevalence and low
BMD common among pts with
HIV
Some ART regimens have larger
impact on BMD loss than others
Assess pts for BMD loss or risk of bone disease depending
on risk factors
For pts at risk for or with BMD loss or bone disease,
consider ART modifications
• Backbone: consider FTC/TAF or ABC/3TC vs
FTC/TDF
• Greater BMD loss observed with PI-based regimens
vs RAL-based regimens
43. Case 3: Preventive Care Considerations for
Healthy Older Patients With HIV
44. Case 3: Presentation
55-yr-old white man transfers care from another state
Characteristic Finding
HIV status
Stable suppression for 15 yrs on
RAL + FTC/TDF; current HIV-1 RNA
undetectable
CD4+ cell count 275 cells/mm3
Family history
Father died from stroke at age 76
Mother breast cancer survivor at
age 75; has T2DM and
hyperlipidemia
Healthy sister age 57
Social
Lives with HIV+ husband; sexually
active with husband only
Smokes on weekends/at bars
Alcohol daily 1-2 glasses of wine
with dinner; no illicit drug use
Characteristic Finding
Additional
findings
Excellent tolerability to HIV meds
Reports irritability because of job
stress but sleeping well
Reports 25-lb weight gain in past 2
yrs; stopped exercising because of
injury to ankle and never resumed
No fevers/chills/night sweats; no
lymphadenopathy
No pulmonary or cardiovascular
complaints; no edema
Normal urine function and bowel
habits
45. Case 3: Presentation
55-yr-old white man transfers care from another state
Characteristic Finding
Physical exam
Vital signs: temp 98.6ºF; pulse rate 80 and regular, BP 146/88 mm Hg,
RR 12, weight 205 lbs, BMI 30.1
PE unremarkable
Laboratory values
Normal lab values: CBC, CMP (except glucose 108 mg/dL)
TC 205 mg/dL, LDL 124 mg/dL, HDL 30 mg/dL, TG 255 mg/dL
STI testing negative
HAV and HBV immune; HCV Ab negative
ASCVD 10-yr risk 20.2%
46. Which disease currently poses a greater risk to
his health?
A. HIV infection
B. Cardiovascular disease
C. Something else
Please respond using your mobile device 1234567891012345678910
47. Keeping Healthy HIV Pts Healthy: How to Beat
Inflammation and Limit Comorbidities
Adhere to HIV medications
Quit smoking
Refine diet and maintain normal weight
– For obese individuals, a hypocaloric diet can reduce inflammation[1]
Exercise
– Study of sedentary HIV-infected pts on ART (N = 49) found that 60 mins brisk
walking ± 30 mins strength training 3 times/wk for 12 wks improved functional
status and reduced inflammatory markers/immune activation[2]
Reduce alcohol intake; avoid drugs
Slide credit: clinicaloptions.com
1. Hermsdorff HH, et al. Endocrine. 2009;36:445-451.
2. Bonato M, et al. BMC Infect Dis. 2017;17:61.
48. HIV Infection Lowers Threshold at Which
Alcohol Causes Harm
Study of alcohol intake and mortality or physiologic injury in HIV-infected (n
= 18,145) and HIV-uninfected (n = 42,228) individuals in the Veterans Aging
Cohort Study
– 76% of HIV-infected pts with HIV-1 RNA < 500 copies/mL
Threshold for association between alcohol and mortality differed by HIV
status
Slide credit: clinicaloptions.comJustice AC, et al. Drug Alcohol Depend. 2016;161:95-103.
HIV Status Threshold, Drinks/Mo Mortality, HR (95% CI)
Infected ≥ 30 1.30 (1.14-1.50)
Uninfected ≥ 70 1.13 (1.00-1.28)
Similarly, lower alcohol threshold for physiologic injury (eg, falls, fractures) in
HIV-infected pts
49. START: Cancer Events With Immediate vs
Deferred ART
INSIGHT START Group. N Engl J Med. 2015;373:795-807. Lundgren J, et al. IAS 2015. Abstract MOSY0302.
Cancer Event, n
Immediate
ART
(n = 2326)
Deferred
ART
(n = 2359)
Total 14 39
Kaposi sarcoma 1 11
Lymphoma, NHL + HL 3 10
Prostate cancer 2 3
Lung cancer 2 2
Anal cancer 1 2
Cervical or testis
cancer
1 2
Other types* 4 9
*Immediate ART: squamous cell carcinoma, plasma cell myeloma, bladder cancer, fibrosarcoma. Deferred ART: gastric
adenocarcinoma, breast cancer, ureteric cancer, malignant melanoma, myeloid leukemia, thyroid cancer, leiomyosarcoma, liver
cancer, squamous cell carcinoma of head and neck.
Time to Cancer Event
10
8
6
4
2
0
Cumulative%WithEvent
0 12 24 36 48 60
Mo
Deferred ART
Immediate ART
Rate/100 PY: immediate, 0.20; deferred, 0.56
(HR: 0.36; 95% CI: 0.19-0.66; P = .001)
Slide credit: clinicaloptions.com
50. HIV and Cancer
Assessment of malignancy in HIV-infected pts in EuroSIDA (N = 15,648)
Slide credit: clinicaloptions.comShepherd L, et al. HIV Med. 2016;17:590-600.
Malignancy Type Malignancy Risk Factors
Infection-related
malignancies
Hodgkin/non-Hodgkin lymphoma (EBV)
Hepatocellular carcinoma (HBV/HCV)
Kaposi sarcoma (HHV-8)
Anal, cervical, vulvar, vaginal, penile, stomach, and
oral cancers (HPV)
Age
Lower CD4+ cell count
HBV coinfection
Detectable HIV-1 RNA
Prior ADM
Infection-
unrelated
malignancies
Lung cancer
Prostate cancer
Colorectal cancer
Breast cancer
Age
Lower CD4+ cell count
HBV coinfection
Current smoking
51. D:A:D: Impact of Smoking Cessation on Cancer
Incidence in HIV-Infected Pts
Baseline characteristics: 72.5% male; 20.8% prior AIDS; 46% current smoker; 20% exsmoker; 31%
never smoked; median age: 40 yrs (IQR: 34-46); median CD4+ cell count: 444 cells/mm3 (IQR: 295-632)
Pts followed for median of 9 yrs (IQR: 6-11)
Shepherd L, et al. CROI 2017. Abstract 131.
Adjusted Rate Ratios for Specific Cancers in 35,424 HIV+ Pts With 285,103 PYFU
Smoking Status Smoking-
Unrelated Cancer
Smoking-Related
Cancer (Excl. Lung)
Lung Cancer
Never (reference)
Current smoker
Ex at baseline
Ex: < 1 yr
Ex: 1-2 yrs
Ex: 2-3 yrs
Ex: 3-5 yrs
Ex: > 5 yrs
Adjusted Rate Ratio (95% CI)
0.5 1 2
P trend
= .04
P trend
= .04
P trend
= .13
0.5 1 2 4 1 2 4 8 16 32
Slide credit: clinicaloptions.com
52. Cancer Prevention
Encourage smoking cessation
Provide hepatitis and HPV vaccinations
Advise sunscreen and avoidance of sun overexposure
Screening:
– Yearly cervical and anal Pap tests as indicated[1]
– Colon cancer screening at age 50[1]
– Breast cancer screening every other yr at age 50[2,3]
– Prostate screening risks and benefits discussed at age 50[2,4]
– If hepatitis B or C positive, screen for liver cancer[1]
Slide credit: clinicaloptions.com
53. Screening With Low-Dose CT Reduces Lung
Cancer Mortality in High-Risk Pts
N = 53,454 persons at high risk for lung
cancer at 33 US medical centers, 2002-
2004[1]
– Randomized to 3 annual low-dose CT
screening vs single-view chest x-ray
– Low-dose CT reduced RR lung cancer
mortality by 20% (95% CI: 6.8% to 26.7%;
P = .004) and RR all-cause mortality by
6.7% (95% CI: 1.2% to 13.6%; P = .02)
USPSTF recommends annual low-dose
CT screening in adults aged 55-80 yrs who
have a 30 pack-yr smoking history and
currently smoke or quit smoking within the
past 15 yrs[2]
1. National Lung Screening Trial Research Team, et al. N Engl J Med. 2011;365:395-409.
2. USPSTF. Lung Cancer Screening Guidelines. 2013.
Cumulative Numbers of Lung Cancers
and Deaths From Lung Cancer
Slide credit: clinicaloptions.com
800
CumulativeNo.
ofLungCancers
600
400
0
200
1000
0 1 2 3 4 5 6 7 8
Low-dose CT
Chest radiography
400
CumulativeNo.of
LungCancersDeaths
300
200
0
100
500
0 1 2 3 4 5 6 7 8
Yrs Since Randomization
Low-dose CT
Chest radiography
1200
54. CT Screening for Lung Cancer in HIV-Infected
Smokers
Prospective CT screening in 224 HIV-positive current or former
smokers aged ≥ 25 yrs detected 1 lung cancer in 678 PYFU
– Median age: 48 yrs (IQR: 44-53); median CD4+ nadir: 179 cells/mm3
(IQR: 61-332)
Hulbert A, et al. J Thorac Oncol. 2014;9:752-759.
Characteristics Adjusted OR for Lung Cancer 95% CI P Value
Increasing age 1.08 1.01-1.15 .02
Increasing pack-yrs 1.09 1.04-1.15 < .0001
Decreasing CD4+ nadir 1.006 1.002-1.01 .006
Increased SD/TLV 1.23 1.03-1.47 .02
Factors Associated With Lung Cancer on Multivariate Regression
Slide credit: clinicaloptions.com
55. ANRS EP48 HIV CHEST: CT Screening for Lung
Cancer in HIV-Infected Smokers
Prospective CT screening in 442 HIV-positive smokers aged
≥ 40 yrs with CD4+ nadir < 350 cells/mm3 detected 9 lung
cancers
– Median follow-up time after CT: 24.4 mos (IQR: 22.8-26.4)
– Median age: 49.8 yrs (IQR: 46.3-53.9); median CD4+ nadir:
168 cells/mm3 (IQR: 75-256)
6 of 9 lung cancers detected by CT were detected at early
disease stage
Makinson A, et al. AIDS. 2016;30:573-582. Slide credit: clinicaloptions.com
56. Case 3: Take-home Points
Observation Recommendations
Healthy aging pts with HIV
should be encouraged to
maintain health and be
aware of increased risk of
HIV-specific comorbidities
Adhere to HIV medications
Quit smoking
Maintain normal weight
Exercise
Reduce alcohol intake; avoid drugs
Cancer risk should be
managed in HIV-infected pts
and screening provided
Encourage smoking cessation
Provide hepatitis and HPV vaccination
Provide cancer screening as indicated
Slide credit: clinicaloptions.com
57. clinicaloptions.com/hiv
Additional slidesets on contemporary management of HIV with expert faculty commentary
Postconference clinical updates available following CROI, the International AIDS
Conference, and IDWeek
Go Online for More CCO
Coverage of HIV!